Exhibit 99.1 BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates 1 - $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patien ...

-$120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue  -As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment  -Attruby continues to differentiate clinically by proving its unique profile in n ...

公司收购公告 - 公司举行电话会议 介绍收购Groupe LAR的详细信息 [1][2] - 更多关于收购的信息可在公司网站的投资者文档中心获取 [3] - 此次收购旨在增加LAR的订单储备 并对公司净业绩和合并收入增长做出贡献 [5] 公司管理层 - 电话会议由首席财务官Jean-François Boucher主持 [1][2] - 董事会主席兼首席执行官Jean Paschini也参与会议并将在结束时回答问题 [2] 前瞻性陈述 - 陈述包含前瞻性内容 反映了公司的目标和预期 [4] - 前瞻性信息涉及交易的效果和益处 以及LAR员工数量增长的预期 [4][5]

PresentationLadies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to the BridgeBio Pharma Autosomal Dominant Hypocalcemia Type 1 ADH1 CALIBRATE Phase III top line results webinar [Operator Instructions] I would now like to turn the conference over to Dr. Neil Kumar, Chief Executive Officer. Dr. Kumar, please go ahead.Neil KumarCo-Founder, CEO & Director Thank you to everyone who joined this call, parti ...

BridgeBio Pharma (NasdaqGS:BBIO) Update / Briefing October 29, 2025 08:00 AM ET Company ParticipantsAndrew Tsai - SVPAnanth Sridhar - COO of CardiorenalMary Scott - Senior Director of Clinical DevelopmentNeil Kumar - CEOScott Adler - Chief Medical OfficerMatt Outten - Chief Commercial OfficerConference Call ParticipantsMani Foroohar - Senior Research AnalystAnupam Rama - AnalystTyler Van Buren - Managing Director and Senior Biotech Equity Research AnalystCory Kasimov - Senior Managing Director and Biotech A ...

- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints  - The primary endpoint was met with 76% of participants administered encaleret achieving both serum and urine calcium within the respective target ranges at Week 24 compared to 4% when on conventional therapy at Week 4 (p<0.0001) - In a key secondary analysis, 91% of participants administered encaleret achieved intact PTH above the lower limit of the reference range at Week 24 compar ...

生物科技与医疗健康股盘后表现 - 多只生物科技和医疗健康股因临床进展、战略合作及监管里程碑等催化剂在盘后交易中出现显著上涨 [1] Genenta Science S.p.A. (GNTA) - 股价在常规交易中下跌27.71%至2.40美元，盘后反弹2.08%至2.45美元 [2] - 波动源于两项重要公告：10月27日公司披露以每股3.50美元的价格进行1500万美元的定向增发，发行429万股ADS，引发投资者对股权稀释的担忧，但所筹资金将用于支持临床开发和平台扩展 [2] - 10月24日公司宣布了一项针对现货型慢病毒载体质粒DNA的战略合作，建立在现有合作伙伴关系基础上 [2] EDAP TMS S.A. (EDAP) - 股价在常规交易中大幅下跌22.58%至1.81美元，盘后反弹8.29%至1.96美元，此次反弹似乎是技术性的，并无新消息发布 [3] - 公司于10月27日宣布其首席执行官和首席财务官计划在2025年11月10日至13日于佛罗里达州举行的UBS全球医疗健康会议上举行一对一投资者会议 [3] BridgeBio Pharma Inc. (BBIO) - 股价在常规交易中上涨1.48%至64.50美元，盘后继续上涨6.71%至68.83美元 [4] - 上涨反映了市场对公司即将公布的针对常染色体显性低钙血症1型的第三阶段CALIBRATE试验结果日益增长的预期，公司计划在10月29日市场开盘前公布顶线数据 [4] OrthoPediatrics Corp. (KIDS) - 股价在常规交易中微跌0.29%至16.91美元，但在发布第三季度财报和运营更新后，盘后飙升6.45%至18.00美元 [5] - 2025年第三季度，公司GAAP每股亏损为0.50美元，非GAAP每股亏损为0.24美元，尽管收入增长了12%，反映了其儿科骨科产品组合的持续需求 [5] - 在运营方面，公司完成了使用VerteGlide脊柱生长引导系统的首次手术，并为其3P儿科钢板平台小-迷你系统（其不断扩大的3P产品家族中的第二个产品）获得了许可 [6] - 公司上调了2025年全年收入指引至2.335亿美元至2.345亿美元区间，预示着较上年增长14%至15% [7] Modular Medical Inc. (MODD) - 股价收盘下跌1.30%至0.5392美元，盘后反弹5.38%至0.5682美元 [8] - 上涨源于公司宣布成功完成了其第一阶段ISO 13485:2016审核，这是获得欧盟医疗器械法规下CE标志认证的关键里程碑，标志着其胰岛素输送平台向欧洲商业化迈进了重要一步 [8] Vivani Medical Inc. (VANI) - 股价在常规交易中上涨3.09%至1.67美元，盘后再涨3.65%至1.7310美元 [9] - 股价对一笔1570万美元融资的完成做出了积极反应，该融资包括一项注册直接发行和一项同步进行的私募配售，值得注意的是董事长Gregg Williams参与了私募配售，显示了内部人士的信心 [9] Amarin Corp. plc (AMRN) - 股价日间下跌1.56%至18.94美元，盘后反弹5.07%至19.90美元 [10] - 此次变动源于FDA决定修订非诺贝特药物的标签，阐明其缺乏心血管益处并强调与他汀类药物联用时的安全风险，这一监管转变可能有利于Amarin的Vascepa，使其在血脂管理领域保持差异化 [10]

PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hypocalcemia type 1 (ADH1) CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Members of management will host a conference call to discuss the data at 8:00 a.m. ET the same day. To access the live webcast for BridgeB ...

股价表现 - BridgeBio Pharma股价在上一交易日大幅上涨17.1%至63.56美元 成交量显著高于平均水平 [1] - 此次上涨使该股过去四周的涨幅达到8.4% [1] 关键临床进展 - 公司公布了针对肢带型肌营养不良症2I/R9型的BBP-418药物三期FORTIFY研究的积极顶线数据 研究达到了所有主要和次要中期分析终点 [2] - BBP-418治疗耐受性良好 未报告新的或意外的安全性问题 [2] - 公司计划在2026年上半年提交BBP-418的新药申请 [2] 财务业绩预期 - 公司预计在即将公布的季度报告中每股亏损0.88美元 同比变化为-2.3% [3] - 预计季度收入为1.0547亿美元 较去年同期大幅增长3763.3% [3] - 过去30天内 对该季度的共识每股收益预期上调了3.1% [4] 行业比较 - BridgeBio Pharma所属行业为医疗-仿制药 同行公司Supernus Pharmaceuticals股价在上一交易日下跌0.2%至52.72美元 [5] - Supernus Pharmaceuticals过去一个月回报率为12.3% [5] - 过去一个月内 Supernus的共识每股收益预期上调14.3%至0.3美元 但较去年同期下降71.7% [6]

Raymond James set a price target of $69 for NASDAQ:BBIO, indicating a potential increase of about 9.17%.BBIO announced positive interim results from its Phase III FORTIFY trial for Limb-Girdle Muscular Dystrophy Type 2I/R9, boosting investor confidence.The company's stock price rose to $63.56, marking a 17.14% increase and reflecting strong market confidence in BBIO's future.BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company focused on developing treatments for genetic diseases. The company is ...